Search / 210 results found

from
to
State

The obesity epidemic in the U.S. is a major health issue, and it’s getting worse. The current national adult obesity rate is 29.7%, but almost half of adults are projected to be obese, not just overweight, by 2030, according to Harvard researchers estimates published in December 2019 in the New England Journal of Medicine. While […]

State
  • Updated

BRYN MAWR, Pa., July 21, 2021 /PRNewswire/ -- James Caplan, a businessman and medical thinker, has introduced and developed a ground-breaking treatment for sickle cell disease, detailed at www.SickleCellRemedy.com. This platform raises awareness about the unique ozone-based treatment for the condition that Caplan has shepherded for more than 30 years.

State
  • Updated

PHILADELPHIA, July 19, 2021 /PRNewswire/ -- Researchers at Children's Hospital of Philadelphia (CHOP) have developed a novel method for producing new antibiotics to combat resistant bacteria. Through an approach that would target bacteria with an antibiotic that is masked by a prodrug, which the bacteria would themselves remove, the researchers identified a method that would allow for development of new, effective antibiotics that could overcome issues of resistance. The findings were published today in eLife.

State
  • Updated

HORSHAM, Pa., July 12, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in combination with pomalidomide and dexamethasone (Pd) for the treatment of adult patients with multiple myeloma who have received at least one prior line of therapy, including lenalidomide and a proteasome inhibitor. The approval follows the regulatory submission to the FDA in November 2020 and marks the sixth indication for DARZALEX FASPRO® in the treatment of multiple myeloma. Findings from the Phase 3 APOLLO study were presented at the 2020 American Society of Hematology (ASH) Annual Meeting and were recently published in The Lancet Oncology.

State
  • Updated

SPRING HOUSE, Pa., July 9, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new three-year data from the long-term extension (LTE) of the STELARA® (ustekinumab) Phase 3 UNIFI study. The data demonstrated the majority (55.2 percent) of adult patients with moderately to severely active ulcerative colitis (UC) who initially responded to treatment with STELARA sustained symptomatic remissiona rates at nearly three years (week 152).1 Furthermore, a majority (96.4 percent) of the patients in symptomatic remissiona at week 152 were corticosteroid-free. These data are being presented today as a digital oral presentation (DOP83) at the 16th Congress of the European Crohn's and Colitis Organisation.1

State
  • Updated

PITTSBURGH, July 8, 2021 /PRNewswire/ -- PANTHERx Rare announced today that it was selected by Mitsubishi Tanabe Pharma America, Inc. (MTPA) as the exclusive U.S. pharmacy distribution partner for EXSERVAN™ (riluzole). The drug, an oral film formulation of riluzole, was approved by the U.S. Food and Drug Administration (FDA) for the treatment of amyotrophic lateral sclerosis (ALS).

State
  • Updated

PITTSBURGH, July 1, 2021 /PRNewswire/ -- Moonstone Nutrition, a Pittsburgh-based startup, has added capsules to its kidney health product line. Moonstone's patented alkali citrate formula  was created by top kidney doctors with ingredients known to prevent the formation of kidney stones.